Inventor · disambiguated record
Matthew Lorenzi
Also filed as: LORENZI MATTHEW · LORENZI MATTHEW V
11 granted patents·8 pending applications·37 citations·filing 1997–2024
86Inventor score
Files withUS HEALTH4ASTEX THERAPEUTICS LTD3BRISTOL MYERS SQUIBB CO3CILAG GMBH INT2JANSSEN BIOTECH INC2
Top patents by PatentIndex Score
19 records- 0190US7297493B2Fibroblast growth factor receptor activating gene 1 and related compositions and methodsUS HEALTH·Filed 2004·Granted Nov 20, 2007·23 cites·20 claims
- 0282US12448455B2Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitorsJANSSEN BIOTECH INC·Filed 2023·Granted Oct 21, 2025·0 cites·23 claims
- 0381US10478494B2FGFR/PD-1 combination therapy for the treatment of cancerASTEX THERAPEUTICS LTD·Filed 2016·Granted Nov 19, 2019·5 cites·17 claims
- 0477US6608181B2Fibroblast growth factor receptor activating gene I and related compositions and methodsUS HEALTH·Filed 2001·Granted Aug 19, 2003·3 cites·75 claims
- 0575US7199227B2Polynucleotides encoding human histone deacetylase HDAC9cBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Apr 3, 2007·3 cites·14 claims
- 0670US2025101123A1Multispecific binding molecules comprising ltbr and edb binding domains and uses thereofCILAG GMBH INT·Filed 2024·Application pending·0 cites
- 0770US2023030983A1Fgfr/pd-1 combination therapy for the treatment of cancerASTEX THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 0868US11879013B2Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitorsJANSSEN BIOTECH INC·Filed 2020·Granted Jan 23, 2024·0 cites·44 claims
- 0965US2020108141A1Fgfr/pd-1 combination therapy for the treatment of cancerASTEX THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1063US6831170B2Fibroblast growth factor receptor activating gene I and related compositions and methodsUS HEALTH·Filed 2003·Granted Dec 14, 2004·0 cites·37 claims
- 1158US7138246B2Methods for identifying or screening for agents that modulate 17β-HSD3BRISTOL MYERS SQUIBB CO·Filed 2005·Granted Nov 21, 2006·1 cites·3 claims
- 1256US7521044B2Human histone deacetylase, HDAC9cBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Apr 21, 2009·0 cites·9 claims
- 1354US2021188990A1Multispecific binding molecules comprising ltbr and edb binding domains and uses thereofCILAG GMBH INT·Filed 2020·Application pending·0 cites
- 1453US7049088B2PRMTs as modifiers of the p53 pathway and methods of useEXELIXIS INC·Filed 2002·Granted May 23, 2006·1 cites·2 claims
- 1548US2004122080A1Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancerFiled 2002·Application pending·0 cites
- 1647US2003224454A1Human solute carrier family 7, member 11 (hSLC7A11)Filed 2003·Application pending·0 cites
- 1741US2005196753A1Human coactivator-associated arginine methyltransferase 1 (hCARM1)Filed 2003·Application pending·0 cites
- 1838US6323316B1Fibroblast growth factor receptor activating gene 1 and related compositions and methodsUS HEALTH·Filed 1997·Granted Nov 27, 2001·1 cites·35 claims
- 1936US2006024665A1PRMTs as modifiers of the p53 pathway and methods of useFRIEDMAN LORI·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →